TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals aged between 19 and 80 years old.~2. The following patients who belong to the low-risk group to the very-high risk group according to 2015 Korean guidelines for the management of dyslipidemia (Committee, KCJ 2016).~   * Very high risk group (coronary artery disease, ischemic stroke, peripheral vascular disease) were not receiving lipid-lowering agents (statins) within 4 weeks of the screening, regardless of LDL-C levels~  * High risk group (carotid artery disease, abnormal aneurysm, diabetes)\* : LDL-C ≥ 100 mg/dl~  * Moderate risk group (2 or more major risk factors)\* : LDL-C ≥ 130 mg/dl~  * Low risk group (less than 1 major risk factors)\* : LDL-C ≥ 160 mg/dl~     * If the patients taka a lipid-lowering agents (statin) within 4 weeks of screening, enrolled them after wash-out for 4 weeks or more.~3. Patients who voluntarily participated in the trial and obtained document consent.~Exclusion Criteria:~1. a history of acute arterial disease (patients with unstable angina myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within 3 months prior to study enrollment)~2. uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥100mmHg)~3. uncontrolled diabetes (hemoglobin A1c ≥9% or fasting glucose ≥160mg/dl)~4. uncontrolled thyroid dysfunction (thyroid stimulation hormone ≥1.5 times the upper limits of normal (ULN))~5. usage of antihyperlipidemic drugs (bile acid sequestrants, fibrates, niacin, etc.) within 4 weeks before enrollment~6. a history of myopathy, rhabdomyolysis or elevated serum creatinine kinase (CK) more than 2 times the ULN~7. chronic kidney disease (serum creatinine ≥2 times the ULN)~8. elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the ULN)~9. a history of drug or alcohol abuse~10. a history of gastrointestinal surgery or gastrointestinal tract disorders~11. hypersensitivity to the components of this drug~12. those who disagree with contraception~13. pregnancy and/or lactation.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 10mg of the generic formulation (rosuvastatin, ROVASRO®) (Type: ACTIVE_COMPARATOR): Taking 10mg of the generic formulation (rosuvastatin, ROVASRO®)
- 10mg of the reference formulation (rosuvastatin, CRESTOR®) (Type: ACTIVE_COMPARATOR): Taking 10mg of the reference formulation (rosuvastatin, CRESTOR®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed ITP patients need of treatment(s) to minimize the risk of clinically significant bleeding primary ITP confirmed by excluding other supervened causes of thrombocytopenia~Exclusion Criteria:~* pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment HCV, HIV, HBsAg seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Oseltamivir Combining HD-DXM (Type: ACTIVE_COMPARATOR): Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )
- HD-DXM (Type: ACTIVE_COMPARATOR): HD-DXM (orally at 40 mg daily for 4d )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years to 80 years.~* Subjects must have documented evidence of a history of atherosclerotic coronary artery disease/surgical revascularization.~* Subjects on a stable medication regimen.~* Body weight 50 kg or greater at screening.~Exclusion Criteria:~* Moderate/severe heart failure or renal impairment.~* Uncontrolled hyperglycemia in subjects with type 1 or type 2 diabetes.~* Receipt of the combination of omeprazole and clopidogrel within 1 month of randomization.~* Subjects whose medical history, condition or medication regimen may interfere with the evaluation of the safety and tolerability of CSL112 (for example significantly altered electrocardiogram (ECG) waveform, hepatobiliary disease, malignancy, thrombocytopenia, etc.)~* Known hypersensitivity to the product components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CSL112 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pethidine Analgesia on Labor Duration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* nullipar-multiparous patients;~* singleton pregnancies 37- 41 weeks (by the last menstrual period).~Exclusion Criteria:~* maternal respiratory rate \< 8 /min,~* maternal bradycardia (\<60 bpm),~* major fetal congenital anomalies,~* uterine scar presence from previous pregnancies,~* malpresentation,~* antepartum hemorrhage,~* multiple pregnancy,~* labor induction,~* chronic systemic disease,~* rupture fetal membranes,~* epidural analgesia.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Pethidine group / study group (Type: None): Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
- control group (Type: None): The patients who received placebo injection were included in the control group. Saline was given in placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T-cell Based Immunotherapy for of Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological proven skin derived progressive metastatic or locally advanced malignant melanoma. Further inclusion criteria: Performance Status 0 to 1, surgical available metastasis, at least one measurable lesion, acceptable CBC and blood chemistry results. Acceptable organ functions.~Exclusion Criteria:~* Patients with a history of any other malignancies less than five years ago. Brain metastases. Other significant illness including severe allergy, asthma, DM, angina pectoris, congestive heart failure, chronic infections, or active autoimmune disease. Treatment with immune suppressive drugs, experimental drugs, or antineoplastic drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 years at the time of informed consent~* Japanese patients with type 2 diabetes~* Patients who have HbA1c ≥ 7.0% and \< 9.0%~Exclusion Criteria:~* Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis~* Patients receiving or requiring treatment with insulin~* Patients with a body mass index (BMI) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2~* Patients with clinically evident renal impairment (estimated glomerular filtration rate \[eGFR\] of \< 45 mL/min per 1.73 m2) or clinically significant renal disease~* Patients with fasting plasma glucose ≥ 240 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-8500a 75 mg once daily (QD) (Type: EXPERIMENTAL): tablets, orally, once daily for up to 28 days
- Placebo (Type: PLACEBO_COMPARATOR): tablets, orally, once daily for up to 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with serologically confirmed chronic hepatitis C~* Participants using and accepting a double method of contraception~Exclusion Criteria:~* Participants not approved by the national treatment guideline or the Interferon Committee for combined pegylated interferon-ribavirin treatment~* Contraindications in the summary of product characteristics of pegylated interferon alpha-2a and ribavirin~* Participants previously treated with pegylated interferon and/or ribavirin~* Hepatitis B and Human Immunodeficiency Virus co-infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegasys + Copegus (Type: None): Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Simvastatin and Ezetimibe on Lipid and Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both sexes, aged from 18 to 75 years, with a body mass index ranging from 25 to 40 kg/m2 and pre-diabetes (impaired glucose tolerance or impaired fasting glucose).~Exclusion Criteria:~* Blood triglyceride concentration \>350 mg/dl and LDL cholesterol \>200 mg/dl, unstable blood pressure, clinical evidences of cardiovascular, hepatic or renal diseases, use of anti-inflammatory agents or others interfering with lipid or glucose metabolism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Simvastatin arm (Type: ACTIVE_COMPARATOR): A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
- Ezetimibe arm (Type: ACTIVE_COMPARATOR): A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
- Simvastatin-Ezetimibe arm (Type: EXPERIMENTAL): To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Relapsed or resistant follicular non-Hodgkin's lymphoma (NHL)~  * No evidence of transformation to high grade or diffuse large B-cell NHL~* CD20 positive with no evidence of transformation~* Achievement of complete remission (CR) or very good partial remission (VGPR) following reinduction chemotherapy with any standard regimen~  * Includes patients who fail to respond to first-line chemotherapy but who achieve CR or VGPR after proceeding directly to second-line chemotherapy~* Platelet count greater than 100,000/mm\^3 after induction chemotherapy and before randomization~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin normal~* ALT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~* Hepatitis B negative~* Hepatitis C negative~Renal:~* Creatinine no greater than 2 times ULN~* BUN no greater than 2 times ULN~Cardiovascular:~* No inadequate cardiac function~Pulmonary:~* No inadequate pulmonary function~Other:~* Not pregnant or nursing~* HIV negative~* No other uncontrolled serious medical conditions~* No other malignancy within the past 5 years except nonmelanoma skin tumors or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* More than 12 months since prior CD20 therapy, including rituximab~* No prior peripheral blood stem cell transplantation~Chemotherapy:~* See Disease Characteristics~* No more than 3 prior chemotherapy regimens for NHL~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to greater than 30% of bone marrow~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resident at Project Samaritan Inc. (PSI)~Exclusion Criteria:~* Past hypersensitivity to mupirocin or glycerol~* Pregnancy~* Lactation~* Expected discharge from PSI in the following month~* Treatment with intranasal mupirocin within the preceding two months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mupirocin ointment (Type: ACTIVE_COMPARATOR): 0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
- Placebo ointment (Type: PLACEBO_COMPARATOR): 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to understand, in the opinion of the investigator, the informed consent form.~* be diagnosed with schizophrenia~* report dissatisfaction with current medication~* have an aspect of schizophrenia management which could potentially benefit from a change in antipsychotic medication~* receive risperidone 4 mg or 6 mg for at least 4 weeks before the start of the study.~Exclusion Criteria:~* Unable to swallow study drug whole with the aid of water~* cannot have received an investigational drug, used an investigational medical device, or participated in a clinical study that altered their medication within 6 months before the first administration of study drug, or have participated in more than 2 investigational drug studies within the past 12 months~* no other major mental health diagnosis except for tobacco dependance~* no use of cocaine or heroin within 3 months before the first administration~* no history of treatment with any antipsychotic in addition to treatment with risperidone, or treatment with paliperidone, within 30 days before the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
- 001 (Type: EXPERIMENTAL): Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interactive Voice Response (IVR)-Based Treatment for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presence of at least a moderate level of pain (i.e., pain scores of \> or = 4) and presence of pain for a period of \> or = 3 months~* ability to participate safely in the walking portion of the intervention as evidenced by ability to walk at least one block~* availability of a touch-tone telephone and computer with internet access in the participant's residence~* Veteran receiving care at VA Connecticut Healthcare System~Exclusion Criteria:~* life threatening or acute medical condition that could impair participation (e.g., severe chronic obstructive pulmonary disease, lower limb amputation, terminal cancer);~* psychiatric condition (e.g., active substance abuse, psychosis or suicidality) that could impair participation~* surgical interventions for pain during their participation in this study~* sensory deficits that would impair participation (e.g., hearing loss to a degree that telephone usage is not possible).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
- Arm 2 (Type: ACTIVE_COMPARATOR): Ten session face to face cognitive behavior therapy for chronic low back pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Cessation Treatment for Teen Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age 14-18 at the beginning of the study~Smoking at least 10 cigarettes per day~At least one quit attempt in previous 6mos~Exclusion Criteria:~Current DSM-IV disorder (depression, panic disorder, social anxiety disorder and agoraphobia)~Current self report of daily or heavy use (more than three times per week) of any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.)~Positive urine pregnancy test~Currently on bupropion (Wellbutrin, Wellbutrin SR, Zyban) or other antidepressants, MAOI's, antipsychotics, benzodiazepines~Currently on NRT~Currently receiving formal treatment for substance abuse problem, depression or anxiety

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Extended treatment (Type: EXPERIMENTAL): extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
- Control group (Type: NO_INTERVENTION): Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete